Findings

What do systematic reviews say?

4,734 questions · 15,288 findings · 893 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,864 · 25.3%GRADE not reported 2,222 · 14.5%Very low 3,868 · 25.3%Low 3,280 · 21.5%Moderate 1,676 · 11%High 378 · 2.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Low molecular weight heparin vs no prophylaxis

Symptomatic DVT · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in symptomatic DVT: assessed by presence of symptoms and confirmed by a… compared with no prophylaxis (low certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.61 [0.18, 2.03]
4 studies · 1848 participants
Low

Low molecular weight heparin vs no prophylaxis

Asymptomatic DVT · adults undergoing KA

It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.14 [0.03, 0.61]
2 studies · 369 participants
Very low

Low molecular weight heparin vs no prophylaxis

All‐cause mortality ( · adults undergoing KA

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1978 participants
GRADE not reported

Low molecular weight heparin vs no prophylaxis

All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 1.85 [0.95, 3.59]
5 studies · 1978 participants
Moderate

Low molecular weight heparin vs no prophylaxis

Major bleeding · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.98 [0.06, 15.72]
1 study · 1451 participants
Moderate

Low molecular weight heparin vs no prophylaxis

Minor bleeding · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 1.79 [0.84, 3.84]
5 studies · 1978 participants
Moderate

Ulipristal acetate (all doses) vs placebo

Duration of bleeding Total bleeding in 90 days (bleeding calendar)

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Mefanamic acid vs Vitex agnus

Menstrual blood loss PBAC score

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mefanamic acid vs Vitex agnus

Nausea

Mefanamic acid showed no clear difference in side effects: nausea compared with vitex agnus; GRADE not reported.

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
OR 1 [0.06, 16.53]
1 participants
GRADE not reported

Mefanamic acid vs Vitex agnus

Abdominal pain

Mefanamic acid showed no clear difference in side effects: abdominal pain compared with vitex agnus; GRADE not reported.

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
OR 0.33 [0.01, 8.22]
0 participants
GRADE not reported

Tranexamic acid vs sodium diclofenac

Pelvic pain

It is very uncertain whether tranexamic acid changes pelvic pain compared with sodium diclofenac (very low certainty).

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
OR 1 [0.06, 17.25]
1 study · 38 participants
Very low

Naproxen vs placebo

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Naproxen vs placebo

Relief of pain

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Low

Naproxen vs placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale)

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Low

Naproxen vs placebo

Additional analgesia required (escape analgesia)

Naproxen showed no clear difference in need for additional analgesia (self‐recorded) compared with placebo (low certainty).

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
OR 0.29 [0.05, 1.8]
1 study · 33 participants
Low

Naproxen vs placebo

Gastrointestinal effects

Naproxen showed no clear difference in side effects: gastrointestinal symptoms compared with placebo (low certainty).

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
OR 2.11 [0.18, 25.17]
1 study · 33 participants
Low

Intervention not reported

Percentage days bleeding or spotting (questionnaire)

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Low

Intervention not reported

Adverse events or side effects

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Menstrual blood loss

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Duration of bleeding Median number of bleed days (diary)

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 168 participants
Low